Alps Group Inc · NASDAQ (us_market)
— · — · —
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-10-31$2.56 RISE2026-03-06$0.88 PEAK2026-03-12$1.18 132d | -65.6% 126d | Missed | Missed | — | — | +33.4% 6d | Missed |
DROP2025-10-31$2.56 RISE2025-12-31$0.87 PEAK2026-03-12$1.18 132d | -66.1% 61d | Missed | Missed | — | — | +35.2% 71d | Missed |
DROP2025-10-31$2.56 RISE2025-11-11$0.60 PEAK2025-11-28$1.54 28d | -76.5% 11d | Missed | Missed | — | — | +155.8% 17d | Missed |
No scored news yet for a sentiment trend.
KUALA LUMPUR, Malaysia, April 17, 2026 -- Alps Group Inc , the parent company of Alps Life Sciences Inc. , a biotechnology research and healthcare platform focused on predictive, preventive, and...
KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a peer-reviewed case study in the February 2026 edition of SAGE Open Medical Case Reports. The publication reports findings from nine patients who received autologous Natural Killer (NK
KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a potential expansion of its exosome-related pipeline beyond its previously disclosed CELESOME(+) program. The announcement follows the publication of a preliminary retrospective clinic
Alps Group Inc (the "Company" or "Alps Group"), the parent company of Alps Life Sciences Inc. ("Alps Holdco"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and
KUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ: ALPS) (the “Company” or “Alps Group”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced the appointment of Cheing Lye-Ping (Penny) as Chief Financial Officer (CFO) of the Company, effective January 5, 2026. Ms. Cheing will be responsible for leading the development of the financial strategy to support the business, incl
Alps Group Inc (NASDAQ: ALPS) (the "Company" or "Alps Group"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced the
Key Insights Significant insider control over Alps Group implies vested interests in company growth The top 2...
Key Insights Significant insider control over Alps Group implies vested interests in company growth The top 2...
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 56.7K | $2.98M | 0.00% | Trimmed-0.5% | 2026-03-31 |
| RenTech | quant | 47.4K | $2.50M | 0.00% | Added+17.4% | 2026-03-31 |